Avid Bioservices Stock Forecast, Price & News

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Avid Bioservices in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Avid Bioservices stock.
View analyst ratings for Avid Bioservices or view top-rated stocks.

3 Wall Street research analysts have issued twelve-month price objectives for Avid Bioservices' shares. Their CDMO stock forecasts range from $22.00 to $30.00. On average, they anticipate Avid Bioservices' stock price to reach $26.67 in the next year. This suggests a possible upside of 74.0% from the stock's current price.
View analysts' price targets for Avid Bioservices or view top-rated stocks among Wall Street analysts.

Avid Bioservices' stock was trading at $29.18 at the start of the year. Since then, CDMO shares have decreased by 47.5% and is now trading at $15.33.
View the best growth stocks for 2022 here.

Avid Bioservices is scheduled to release its next quarterly earnings announcement on Wednesday, September 14th 2022.
View our earnings forecast for Avid Bioservices.

Avid Bioservices, Inc. (NASDAQ:CDMO) posted its earnings results on Tuesday, December, 7th. The biopharmaceutical company reported $0.06 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.02 by $0.04. The biopharmaceutical company had revenue of $26.11 million for the quarter, compared to analysts' expectations of $25 million. Avid Bioservices had a trailing twelve-month return on equity of 27.58% and a net margin of 12.13%. During the same quarter in the previous year, the firm earned $0.01 earnings per share.
View Avid Bioservices' earnings history.

Shares of Avid Bioservices reverse split on the morning of Monday, July 10th 2017. The 1-7 reverse split was announced on Friday, July 7th 2017. The number of shares owned by shareholders was adjusted after the market closes on Friday, July 7th 2017. An investor that had 100 shares of Avid Bioservices stock prior to the reverse split would have 14 shares after the split.

Avid Bioservices issued an update on its FY 2023 earnings guidance on Wednesday, June, 29th. The company provided EPS guidance of for the period. The company issued revenue guidance of $140.00 million-$145.00 million, compared to the consensus revenue estimate of $146.50 million.

2 employees have rated Avid Bioservices CEO Roger Lias on Glassdoor.com. Roger Lias has an approval rating of 49% among Avid Bioservices' employees. This puts Roger Lias in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Avid Bioservices include Zai Lab (ZLAB), Karuna Therapeutics (KRTX), Turning Point Therapeutics (TPTX), Galapagos (GLPG), Cytokinetics (CYTK), Bausch Health Companies (BHC), Harmony Biosciences (HRMY), AbCellera Biologics (ABCL), Amicus Therapeutics (FOLD), Prestige Consumer Healthcare (PBH), PTC Therapeutics (PTCT), Blueprint Medicines (BPMC), Corcept Therapeutics (CORT), CureVac (CVAC) and Indivior (INVVY).
View all of CDMO's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Avid Bioservices investors own include Array Technologies (ARRY), Anavex Life Sciences (AVXL), Inovio Pharmaceuticals (INO), Advanced Micro Devices (AMD), Dynavax Technologies (DVAX), Micron Technology (MU), QUALCOMM (QCOM), NVIDIA (NVDA), Novavax (NVAX) and Pfizer (PFE).

Avid Bioservices trades on the NASDAQ under the ticker symbol "CDMO."

Shares of CDMO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CDMO stock can currently be purchased for approximately $15.33.

Avid Bioservices (NASDAQ:CDMO) has a market capitalization of $946.54 million and generates $95.87 million in revenue each year. The biopharmaceutical company earns $11.21 million in net income (profit) each year or $0.159990 on an earnings per share basis.

Avid Bioservices employs 252 workers across the globe.

Avid Bioservices' mailing address is 2642 Michelle Drive Suite 200, TUSTIN CA, 92780. The official website for Avid Bioservices is www.avidbio.com. The biopharmaceutical company can be reached via phone at (714) 508-6100, via email at [email protected], or via fax at 714-838-5817.